
    
      This is a single-center, nonrandomized, open-label study to evaluate the safety and clinical
      activity of ThisCART19 in patients with refractory or relapsed CD19 positive B cell
      malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. The dose range
      is 0.2-60 x 10^6 cells per kg body weight.
    
  